FDA Authorizes More Covid-19 Vaccine Doses From Troubled Baltimore Plant

United States News News

FDA Authorizes More Covid-19 Vaccine Doses From Troubled Baltimore Plant
United States Latest News,United States Headlines
  • 📰 WSJ
  • ⏱ Reading Time:
  • 15 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 63%

The FDA cleared an additional batch of 15 million J&J Covid-19 vaccine doses from a troubled production plant in Baltimore

. The Baltimore contract-manufacture site, run by Emergent BioSolutions Inc., originally made vaccines for J&J and another vaccine company, AstraZeneca PLC. By this spring, the FDA found that Emergent hadn’t taken measures to avoid cross-contamination between the two vaccine lines.

There are still more than 100 million vaccine doses or unbottled dose equivalents in the plant’s inventory, from both companies, awaiting FDA action. The agency is expected to make a decision on the AstraZeneca vaccine later this week or next week, according to the senior U.S. official.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

WSJ /  🏆 98. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Africa to be a priority for G7's donated COVID-19 vaccine doses- WHOAfrica to be a priority for G7's donated COVID-19 vaccine doses- WHOAfrica will get priority treatment for the Group of Seven's pledged 870 million doses of COVID-19 vaccine, a senior World Health Organization adviser said on Monday.
Read more »

3 COVID-19 vaccine doses can improve immunity in solid organ transplant recipients: Study3 COVID-19 vaccine doses can improve immunity in solid organ transplant recipients: StudyAn extra boost of a vaccine may mean more protection for organ transplant recipients in their fight against COVID-19, a new study finds.
Read more »

Study: Nearly a quarter of COVID-19 patients developed new or long-term conditionsStudy: Nearly a quarter of COVID-19 patients developed new or long-term conditionsAbout 23% of COVID-19 patients have developed at least one 'persistent or new' medical condition more than four weeks after their initial diagnosis, according to a new study from FAIR Health. Why it matters: New post-COVID symptoms were discovered across different age groups. The five most common were pain, difficulty breathing, high cholesterol, malaise and fatigue, and high blood pressure, reports the New York Times.Stay on top of the latest market trends and economic insights with Axios Marke
Read more »

New Guidance Issued On Covid-19 Vaccines For People With CancerNew Guidance Issued On Covid-19 Vaccines For People With CancerThe four-page guide answers common questions about Covid-19 vaccines for people with cancer and their caregivers.
Read more »

Colombia Protest Leaders Halt Demonstrations as Covid-19 Cases RageColombia Protest Leaders Halt Demonstrations as Covid-19 Cases RageThe leaders of a protest movement that has rocked Colombia for seven weeks on Tuesday called off demonstrations amid a spike in Covid-19 cases that the government partly blames on the mass mobilizations
Read more »



Render Time: 2025-03-26 07:27:51